Coinhibitory molecules, such as PD-1, CTLA-4, 2B4, and BTLA, are an important new family of mediators in the pathophysiology of severe bacterial and/or fungal infection, as well as the combined insults of shock and sepsis. Further, the expression of these molecules may serve as indicators of the immune status of the septic individual. Using PD-1:PD-L as an example, we discuss in this review how such checkpoint molecules may affect the host response to infection by mediating the balance between effective immune defense and immune-mediated tissue injury. Additionally, we explore how the up-regulation of PD-1 and/or PD-L1 expression on not only adaptive immune cells (e.g., T cells), but also on innate immune cells (e.g., macrophages, monocytes, and neutrophils), as well as nonimmune cells during sepsis and/or shock contributes to functional alterations often with detrimental sequelae.
Systemic inflammatory response syndrome/compensatory anti-inflammatory response syndrome
The central hypothesis that has driven the search for novel therapeutics is that sepsis induces an overwhelming systemic inflammatory response syndrome (SIRS). Sequelae include significant bystander cell/tissue injury within the host. Although the term SIRS has been largely overtaken by the modified definition encompassing an expanded pathophysiologic perspective of sepsis, the underlying principle of SIRS has historically influenced the framework with which sepsis has been researched. 6, 9, 10 Unfortunately, however, although numerous treatments that were based on anti-inflammatory or anticoagulant concepts showed promise in the experimental setting, they have all failed to provide a survival benefit in randomized human clinical trials. 11, 12 And although one can argue the nature and quality of the clinical trials designed to test these anti-inflammatory approaches, it remains critical to continue to work toward a better understanding of the complex pathology of the septic state in order to develop a truly effective therapy.
The term compensatory anti-inflammatory response syndrome (CARS) was coined by Roger Bone to describe the immune suppression that occurs after sepsis. 13 It arose from the initial descriptions of the development of immune suppression associated with severe shock/trauma/sepsis and with reports dating back to as early as the 1960s. The syndrome is characterized by the immune system undergoing reduced activation with limited efficacy; in its most severe form, it has even been referred to as immunoparalysis. [14] [15] [16] [17] [18] [19] [20] Historically, however, this facet of the severely injured or septic patient has not been considered as a significant therapeutic target. 
CENTRAL QUESTION
Out of this history grew the principal question which we undertake to review here: does modulating aspects of developing immune suppression improve the capacity of the critically ill patient to ward off endorgan and tissue injury that thus far has been commensurate with the septic state? Specifically, what roles do such coinhibitory/checkpoint protein signaling cascades play in this process of immunomodulation, and how does this affect the balance of innate and/or adaptive immunity?
OBJECTIVES
From our central question, we derived 4 objectives for this discussion, as follows:
1. To provide a succinct overview of membrane costimulatory/ coinhibitory molecules and their role in classic immunity;
2.
To discuss how sepsis and sepsis plus hypovolemic shock affect the expression of coinhibitory molecules such as PD-1 and its ligands;
3.
To describe the data that speak to the pathophysiologic contributions of PD-1:PD-Ls to the morbidity/mortality seen in models of sepsis and/or shock (hemorrhage); and 4. To consider possible adaptive and innate immune mechanisms by which PD-1:PD-L1 interactions may drive morbidity. behind what has been characterized as a Th1-driven response into an activated effector T cell (cell-mediated immunity) response. Alternatively, if the APC expresses a preponderance of coinhibitory molecules (i.e., checkpoint proteins), the CD4 + or CD8 + T lymphocytes are not licensed to respond (i.e., becoming anergic and potentially apoptotic). It should be noted that many of these coinhibitory cell surface receptor molecules actively signal -the simple overexpression of these receptors, or their cell surface ligands in some cases (e.g., the most overt example being the overexpression of some of these coinhibitory lig- 24 That such shifting occurs in the setting of the experimental animal and septic patient has been documented by several labs. 19, 23 Ultimately, these receptors and their ligands are often first regarded as toleragens. 25, 26 Checkpoint proteins are not limited to solely the APC to T cell interaction. Communication among monocytes/macrophages/DCs with epithelial/endothelial/tumor cells works via this mechanism (Fig. 2) .
DISCUSSION

The role of checkpoint proteins in classic Ag-driven immunity
PD-1
PD-1, with pseudonyms including Pcdc1 and CD279, is a Type I transmembrane glycoprotein-Ig (IgV) superfamily member, containing an ITIM and an immunoreceptor tyrosine-based switch motif (ITSM) for intracellular signaling. PD-1 participates across a spectrum of immune responses relative to many other B7:CD28 superfamily members. [27] [28] [29] Most observations indicate that ligation of PD-1 recruits phosphatases Src homology region 2 domain-containing phosphatase (SHP)-1 and/or SHP-2, prompting an inhibition of PI3K pathway signaling resulting typically from CD28/CD3/ITAM activation [30] [31] [32] [33] [34] (Fig. 3) .
PD-L1, also known as B7-H1 or CD274, is considered the primary ligand of PD-1. Importantly, it is ubiquitously expressed on not only immune, but also a wide variety of nonimmune tissues and organs. [35] [36] [37] Alternatively, PD-L2 is more restrictively expressed on APCs and immune cells. 38 
Checkpoint proteins and their ligands during sepsis and shock
Studies from several laboratories initially utilizing experimental models of sepsis, and subsequently models complexed with aspects of severe shock or secondary infectious challenge, have shown that several of these families of cell-surface molecules have an impact on survival. This points to potential roles in pathologic processes driving sepsis. Studies by Huang et al. 47 showed that mice in which the gene for PD-1 was deleted exhibited a marked reduction in mortality in response to cecal ligation and puncture (CLP)-induced polymicrobial septic challenge. From an experimental perspective, the role of PD-1:PD-L ligation in driving these morbid effects was further corroborated by 2 independent investigations utilizing antibodies against PD-1, 33 and its primary ligand PD-L1, 48 where both demonstrated that CLP morbidity and mortality could be significantly reduced by Among adult septic patients and septic adult mice, BTLA and HVEM are both elevated on myeloid and lymphoid cell populations. 55, 56 Unsinger et al. 57 have also shown that in response to septic challenge, expression of CTLA-4 on CD4, CD8, and regulatory T cells 
From PD-1 to its ligands
Similar to the survival analysis undertaken for PD-1 −/− mice, a survival analysis of PD-L1 gene-deficient mice after sepsis demonstrated comparable results. 61 In this respect, elevated PD-L1 and PD-L2 expression has been documented in pulmonary epithelia from patients who died of sepsis. 62 These investigators found that not only the expression of PD-1, but also the expression of its 2 ligands PD-L1
and PD-L2, re associated with poor outcome in sepsis and shock.
Other groups have also reported the expression of the ligands for providing a survival benefit to CLP mice. 59 Since many coinhibitory receptors, for example, PD-1, BTLA, CD47, and CTLA-4, express an ITIM and/or ITSM, it is thought that the suppression of classic CD4 + /CD8 + T cell function is a result of the recruitment of the phosphatase, SHP-1 and/or SHP-2. 27, 30, 66 These SHPs then antagonize not only T cell receptor driven, but other pathways that drive the activation of the Akt/ PI3K pathway, which underpin the immune-suppressed "exhausted" T cell phenotype seen with PD-1 in conditions such as cancer and viral infection. 27, 30, 66 In this respect, studies by Bandyopadhyay et al. 67 have documented that, at least in T lymphocytes isolated from severely injured patients, which they have previously reported as expressing a number of coinhibitory molecules as well as exhibiting T cell anergy/"exhaustion," 21, 68 indicate that these cells appeared hyperresponsive to expressing the activated form of the phosphatase SHP-1 (Fig. 3) . Importantly, Huang et al. 47 
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Secreted inhibitors
Secreted inhibitors ( Fig. 3) . Much, however, remains to be understood about sepsisinduced changes in T cell coinhibitor molecule signaling and how it shapes the septic cellular phenotype and function. 74 in and out the lung in response to an infection, as well as distally to a septic source in the abdomen. 75, 76 iNKT cells are themselves regulated by coinhibitory/checkpoint proteins, most notably PD-1. Initial activation of iNKT cells is associated with increased PD-1 expression upon iNKT cells 77 (Fig. 4 anti-and proinflammatory factors in a direct ARDS mouse model. 87 More recently, a study by Ehrentraut et al. 88 has indicated that CD73-dependent adenosine generating Tregs could promote the resolution of LPS-induced direct ARDS. However, none of these studies illustrated a specific role of Tregs in iARDS. Using a 2-hit model of hemorrhage-CLP (Hem-CLP), Venet et al. 89 observed that CD4 + CD25 + Foxp3 + cells appeared to be recruited to the lung in iARDS and that the Foxp3 as well as IL-10 gene expression in these cells were increased during this process. Most importantly, Venet et al. 89 also showed that down-regulation of the Tregs' function using Foxp3 targeting siRNA, administered 12 h before the induction of experimental iARDS, echoed lung injury obtained in CD4-gene deficient as well as anti-CD4 Ab depleted mice; this was consistently associated with a reduction in lung IL-10 levels. 89 However, how the activation of this small subpopulation of lymphocytes regulated iARDS in this study was only reported to be a strong inducer of PD-1 expression. 49 In fact, Guignant et al. 49 noted that monocytes derived from patients with severe sepsis express both PD-1 and PD-L1 out to 3-5 days post diagnosis of sepsis.
These initial studies by Huang et al. 47 also showed that following CLP, there was a decline in both phagocytic capacity (which occurs with both opsonized and nonopsonized targets) and stimulantinduced cytokine production among macrophages. Additionally, random migratory capacity (measured both in rate and direction) and cell spreading (following surface adherence) increased markedly after sepsis among WT mice. Importantly, these phenomena were equivalent to findings among sham control samples in the setting of PD-1 gene deficiency. 96 These latter changes in migratory capacity, cell to clearance of the invading pathogen. 97 However, it is also thought that the recruitment of activated PMNs may be harmful when these functions are directed at otherwise normal host tissue (bystander injury). 97, 98 In this regard, Ayala et al. 99 and Lomas et al. 100 reported on PMNs that were isolated from donor animals after hemorrhage (a form of PMN priming) (Fig. 4, Component 5 ), and were then adoptively transferred into naïve animals. They found that when these naïve animals were then subjected to a septic challenge, the recipient lungs became inflamed. In this setting, PMN in vivo "priming" was not only associated with an increase in respiratory burst capacity in vitro, but also with a decrease in PMN A o 99,100 ; a finding confirmed by others in experimental iARDS. 101 Jimenez et al. 98 found a significant decline in PMN A o in patients with SIRS and the plasma from these individuals suppressed A o of PMNs derived from healthy controls. 98 These findings and others [102] [103] [104] support the hypothesis that while delayed A o in an infectious environment aids PMN-mediated pathogen killing, in a pathogen-free setting, delay in A o contributes to inflammation/SIRS and organ failure/injury. 98 With that stated, the mechanisms underpinning these effects in PMN have not been fully clarified.
As mentioned earlier, although it has been documented that neutrophils can express the coinhibitory ligand PD-L1, 61 showed that PMNs from CLP mice and patients diagnosed with severe sepsis exhibited a substantial rise in their PD-L1 expression, correlating with increased morbidity in the septic patients. Additionally, these cells, via direct contact, were capable of inducing a marked increase in lymphocytic cell death/dysfunction (another common feature of the septic animal/patient) as well as altering the migrational functionality of the cell (a dysfunction also noted by Young et al. 106 in septic mouse iNKT cells). 22 More recently, Patera et al. 53 
End-organ sequelae of cellular immune disharmony 4.4.1 End-organ injury -the gut
In the intestine, the epithelial lining serves as an important barrier to prevent the absorption of toxins, Ags, and microorganisms across the intestinal wall. Intestinal barrier dysfunction and increased intestinal permeability are morbid states that often accompany developing sepsis. This developing epithelial cell (EpiC) barrier dysfunction has been thought to contribute to the development of the multiple organ dysfunction syndrome during sepsis. [107] [108] [109] Studies have shown that human gastric EpiCs constitutively express basal levels of PD-L1, but when exposed to Helicobacter pylori, this expression significantly increases. 65 PD-L1 mRNA was also detected in colonic EpiCs from healthy individuals and PD-L1 protein expression has been reported on the surface of colonic EpiCs from patients with inflammatory bowel disease. Interestingly, blockade of PD-L1/B7-H1 ligation has been shown to suppress the development of experimental chronic intestinal inflammation, [63] [64] [65] which implies that this ligand could be involved in mediating aspects of gastrointestinal dysfunction seen in septic or traumatic pathologies. In this vein, Huang et al. 61, 110 showed that jejunal villus injury was evident on histologic analysis as well splenic A o in CLP mice-2 findings, which were ameliorated upon deletion of either PD-1 or its primary ligand PD-L1 (B7-H1) gene.
However, a pathomechanistic basis for these findings in the gut were not further explored in those studies.
In this respect, Wu et al. 111 partial, yet significant, restoration of tight junction protein expression on an EpiC line that had lost such expression when subjected to inflammatory stimuli, as encountered in septic animals and septic patients. 111 Taken together, these data support the concept that blockade of PD-1's primary ligand PD-L1, and not just PD-1 itself, has a restorative effect on gut histology and function in the face of experimental septic challenge (Fig. 4, Component 4 ). These characteristics are in contrast to the vascular ECs, which have a continuous basement membrane, express CD31, secrete inflammatory mediators such as IL-6, and directly interact with the intraluminal leukocytes during an inflammatory state by expressing selectins. [112] [113] [114] Hutchins et al. 115 explored the LSEC population's response to experimental septic challenge in relation to PD-L1 expression and found that indeed its increased expression appears to contribute to LSEC dysfunction and liver injury in response to CLP (Fig. 4 
End-organ injury -the liver
End-organ injury -the lung
Using an experimental model of sequential hemorrhagic shock (Hem)
followed by CLP, which is reported to more consistently produce a condition clinically resembling moderate ARDS, pulmonary pathophysiology has been studied. This was chosen over the model of standalone CLP because the combination of insults consistently produced moderate or worse acute pulmonary injury in the setting of a low lethality rate at 24 h. 99, 117 Among WT mice after Hem-CLP, the P:F ratio (arterial P02:Fi02)
decreases, suggesting loss of pulmonary compliance. 99, 118 Among mice who were either PD-1 −/− or PD-L1 −/− , indices of lung inflammation (e.g., IL-6, MIP-2, myeloperoxidase) and injury (pulmonary edema, protein leak) were mitigated following the same Hem-CLP challenge. 99, 119 Histologic analysis has also revealed increased leukocyte presence and cellular A o in lung tissue following Hem-CLP, a finding attenuated by PD-1 gene deletion. 119 
The interface of endothelium with epithelium
The lung, similar to the gut (with its epithelial-lined digestive system interacting with villous endothelium) and the liver (with sinusoidal tissue interacting with robust trees of vascular endothelium), has an interface of these 2 cellular lining entities, namely the endothelium IT delivery of naked siRNA to target pulmonary epithelial cells and intravenous delivery of liposomal-encapsulated siRNA to target vascular endothelial cells were undertaken. 126, 127 The results support the concept that PD-L1 expression on the EC, but not on the pulmonary EpiC, contributes to shock/sepsis-induced iARDS as produced in mice. [126] [127] [128] In ex vivo studies, PD-L1 gene deficiency also renders the lung EC monolayer more resilient against tight junction loss following IFN-/TNF-stimulation (Fig. 4 , Component 4). 
CONCLUSIONS
The future of checkpoint proteins in sepsis
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